NCT00157716View on ClinicalTrials.gov

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

PHASE2CompletedINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

April 30, 2004

Study Completion Date

October 31, 2005

Conditions
Coronary Artery Bypass Graft SurgeryMyocardial IschemiaReperfusion InjuryMyocardial Revascularization
Interventions
DRUG

(MC-1) Pyridoxal-5'-phosphate

Trial Locations (2)

27710-7510

Duke University Medical Center, Durham

H1T 1C8

Montreal Heart Institute, Montreal

Sponsors

Lead Sponsor

Medicure
All Listed Sponsors
lead

Medicure

INDUSTRY

NCT00157716 - MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery) | Biotech Hunter | Biotech Hunter